ExCellThera is an advanced clinical stage delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

Contrary to popular belief, Lorem.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

Contrary to popular belief, Lorem.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.

ExCellThera’s lead solution, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system for the proprietary expansion and reengineered graft composition of Cord Blood Units to provide a one- time treatment to patients suffering from blood cancers and other blood disorders.